Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board called The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical pharmacy are discussed on The F.I.X.
Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The September 2000 Formulary monographs are tegaserod, insulin aspart, tiptorelin pamoate, ziconotide, and bexarotene gel. The DUE is on low-molecular weight heparins and heparinoid.
Get full access to this article
View all access options for this article.
References
1.
Zyvox package literature.Pharmacia & Upjohn Company; April 2000.
2.
SwaneyS.M.The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother.1998; 42: 3251–5.
3.
ShinabargerD.L.Mechanism of action of oxazolidinones: Effects of line-zolid and eperezolid on translation reactions. Antimicrob Agents Chemother.1997; 41: 2132–6.
4.
GemmellC.G., FordC.W.Expression of virulence factors by gram-positive cocci exposed to sub-MIC levels of line-zolid [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. September 26–29, 1999: 1537.
5.
ZurenkoG.E.In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother.1996; 40: 839–45.
6.
SchaadtR.D.Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid. Diagn Microbiol Infect Dis.1997; 28: 201–4.
7.
ZaoutisT.In vitro activity of linezolid (U-100766) and quinupristin/dalfopristin against vancomycin-tolerant group C and group G streptococci [abstract]. 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia. November 18–21, 1999: P124.
8.
DresserL.D., RybakM.J.The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy.1998; 18: 456–62.
9.
StalkerD.J.Linezolid safety, tolerance, and pharmacokinetics following oral dosing twice daily for 14.5 days [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto. September 28–October 1, 1997: A-115.
10.
BiedenbachD.J., JonesR.N.Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents. J Clin Microbiol.1997; 35: 3198–202.
11.
WiseR.The in-vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother.1998; 42: 721–8.
12.
JohnsonA.P.Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom. J Antimicrob Chemother.2000; 45: 225–30.
13.
NoskinG.A.In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother.1999; 43: 2059–62.
14.
JonesM.E.Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and non-quinolones linezolid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains. Antimicrob Agents Chemother.1999; 43: 421–3.
15.
von EiffC., PetersG.Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci. J Antimicrob Chemother.1999; 43: 569–73.
16.
KaatzG.W., SeoS.M.In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother.1996; 40: 799–801.
17.
MulazimogluL.In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother.1996; 40: 2428–30.
18.
JorgensenJ.H.In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species. Antimicrob Agents Chemother.1997; 41: 465–7.
19.
RybakM.J.Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother.1998; 42: 721–4.
20.
CercenadoE.Activity of different antimicrobial combinations against methicillin- and teicoplanin-resistant coagulase-negative staphylococci: Utility of the E-test for the determination of the effects of antimicrobial combinations [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. September 26–29, 1999: 880.
SpanglerS.K.Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother.1996; 40: 481–4.
23.
MasonE.O.JrIn vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae. Antimicrob Agents Chemother.1996; 40: 1039–40.
24.
EliopoulosG.M.In vitro activities of new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother.1996; 40: 1745–7.
25.
BosticG.D.Comparative in vitro and bactericidal activity of oxazolidinone antibodies against multidrug-resistant enterococci. Diagn Microbiol Infect Dis.1998; 30: 109–12.
26.
StruwigM.C.In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci. Antimicrob Agents Chemother.1998; 42: 2752–5.
27.
PatelR.In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis.1999; 34: 119–22.
28.
CercenadoE.Effect of linezolid with vancomycin against highly vancomycin-resistant enterococci: Utility of the E-test for the determination of the effects of antimicrobial combinations [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. September 26–29, 1999: 881.
29.
LindenP.Isolated of a vancomycin-resistant enterococci strain with reduced susceptibility to linezolid [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. September 26–29, 1999: 1105.
30.
GoldsteinE.J.C.Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans. Antimicrob Agents Chemother.1999; 43: 1469–74.
31.
FordC.W.In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob Agents Chemother.1996; 40: 1508–13.
32.
JonesR.N.In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrobial Agents Chemother.1996; 40: 720–6.
33.
JonesR.N.Antimicrobial activity of linezolid (formerly U-100766) tested against 3,808 strains of gram-positive organisms having resistance to various drugs [abstract]. 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia. November 18–21, 1999: P97.
34.
ZurenkoG.E.Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. September 26–29, 1999: 848.
35.
MurphyD.Approval letter for NDA 21-130, NDA 21-131, and NDA 21-132. Center for Drug Evaluation and Research. Food and Drug Administration.Department of Social and Health Services. April 18, 2000. http://www.fda.gov/cder/foi/label/2000/21130lbl.pdf
36.
CirincioneB.The development of a population pharmacokinetic (PK) model for linezolid [abstract]. 39th Inter-science Conference on Antimicrobial Agents and Chemotherapy. San Francisco. September 26–29, 1999: 1205.
37.
SissonT.L.Effect of age and gender on the single-dose pharmacokinetics of linezolid [abstract]. 39th Inter-science Conference on Antimicrobial Agents and Chemotherapy, San Francisco. September 26–29, 1999: 1194.
38.
DiekemaD.J., JonesR.N.Oxazolidinones: A review. Drugs.2000; 59: 7–16.
39.
StalkerD.J.Linezolid safety, tolerance, and pharmacokinetics after intravenous dosing twice daily for 7.5 days [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto. September 28–October 1, 1997: A-116.
40.
Abdel-RahmanS.M., KearnsG.L.An update on the oxazolidinone antibiotics. Pediatr Infect Dis J.1999; 18: 1101–2.
41.
SissonT.L.A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam. J Clin Pharmacol.1999; 39: 1277–82.
42.
TurnakM.R.Multiple-dose pharmacokinetics of linezolid—200, 400, and 600 mg PO Q.12 H [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego. September 24–27, 1998: A-51.
43.
FeenstraK.L.Metabolism and excretion of the oxazolidinone antibiotic linezolid (PNU 100766) following oral administration of [14C]PNU 100766 to healthy human volunteers [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego. September 24–27, 1998: A-53.
44.
WienkersL.C.In vitro metabolism of linezolid (PNU-100766): Lack of induction or inhibition of cytochrome P450 enzymes and studies on the mechanism of formation of the major human metabolite, PNU-142586 [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco. 26-29 September 1999: 11.
45.
BrierM.E.Pharmacokinetics of linezolid in subjects with various degrees of renal function and on dialysis [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego. September 24–27, 1998: A-54.
46.
CammarataS.K.Efficacy of linezolid in gram-positive infections: Results from two phase II trials [abstract]. Pharmacotherapy.2000; 20: 349.
47.
CammarataS.K.Efficacy of linezolid in pneumonia due to penicillin intermediate and resistant Streptococcus pneumoniae [abstract]. 9th International Congress on Infectious Disease (ICID), Buenos Aires, Argentina. April 10–13, 2000.
48.
CammarataS.K.Linezolid in the treatment of community-acquired pneumonia: The results of Phase II and Phase III studies [abstract]. 9th International Congress on Infectious Disease (ICID), Buenos Aires, Argentina. April 10–13, 2000.
49.
LobeckF.Linezolid in the treatment of community-acquired pneumonia in hospitalized children: An open-label, single-arm, multicenter study [abstract]. 9th International Congress on Infectious Disease (ICID), Buenos Aires, Argentina. April 10–13, 2000.
50.
LeachT.S.Linezolid for the treatment of community- or hospital-acquired pneumonia caused by Staphylococcus aureus: Results of four randomized Phase III trials [abstract]. 9th International Congress on Infectious Disease (ICID), Buenos Aires, Argentina. April 10–13, 2000.
51.
BrussJ.B.Comparison of linezolid to oxacillin followed by oral dicloxacillin in the treatment of complicated skin infections: Results from a Multinational Phase III Trial [abstract]. 9th International Congress on Infectious Disease (ICID), Buenos Aires, Argentina. April 10–13, 2000.
52.
DuvallS.E.Comparison of linezolid to oral clarithromycin in the treatment of uncomplicated skin infections: Results from a Multinational Phase III Trial [abstract]. 9th International Congress on Infectious Disease (ICID), Buenos Aires, Argentina. April 10–13, 2000.
53.
BrussJ.B.Linezolid in the treatment of cellulitis and erysipelas: Combined results from four Phase III multinational clinical trials [abstract]. 9th International Congress on Infectious Disease (ICID), Buenos Aires, Argentina. April 10–13, 2000.
54.
LeachT.S.Linezolid versus vancomycin for the treatment of MRSA infections: Results of a randomized Phase III trial [abstract]. 9th International Congress on Infectious Disease (ICID), Buenos Aires, Argentina. April 10–13, 2000.
55.
BirminghamM.C.Outcomes with linezolid (LZD) from an ongoing compassionate use (CU) trial of patients (Pts) with significant, resistant, Gram-positive infections [abstract]. 39th Inter-science Conference on Antimicrobial Agents and Chemotherapy, San Francisco. September 26–29, 1999: 1098.
56.
BirminghamM.C.Results of treating bacteremic patients with linezolid in a compassionate use trial for resistant, gram-positive infections [abstract]. 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia. November 18–21, 1999: P129.
57.
NoskinG.A.Linezolid (LZD) for the treatment of vancomycin-resistant enterococci (VRE) in immunocompromised hosts [abstract]. 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia. November 18–21, 1999: P133.
58.
ChienJ.W.Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin Infect Dis.2000; 30: 146–51.
59.
NoskinG.A.Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin. Clin Infect Dis.1999; 28: 689–90.
60.
AntonyS.J.Methicillin-resistant Staphylococcus aureus infection in a renal allograft recipient treated successfully with a novel new antimicrobial agent (linezolid): New treatment options for infections due to resistant organisms. Clin Infect Dis.1999; 29: 1341–2.
61.
GrahamC.S.Clearance of vancomycin-resistant Enterococcus faecium with linezolid in a liver transplant patient [abstract]. 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia. November 18–21, 1999: P218.
62.
McNeilS.A.Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with Synercid (quinupristin/dalfopristin). Clin Infect Dis.2000; 30: 403–4.
63.
HyattJ.M.Safety and efficacy of linezolid (PNU-100766) in eradication of nasal Staphylococcus aureus [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego. September 24–27, 1998: A-4.
64.
WilksN.E.Safety and tolerance of linezolid in phase II trials [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. September 26–29, 1999: 1763.
65.
MartinJ P.Although a novel microtiter-plate assay demonstrates that linezolid (PNU-100766) is a weak, competitive (reversible) inhibitor of human monoamine oxidase (MAO A), no clinical evidence of MAO A inhibition in clinical trials has been observed [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego. September 24–27, 1998: A-85.
66.
RybakM.J.In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother.2000; 44: 1062–6.
